leisure time -WSS

leisure time

author：comprehensive 2025-10-02 19:15:55 - browse：2

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why drug prescriptions should include diagnoses

WSS

Carbon Health diabetes program, a test of data

Carbon Health diabetes program, a test of data

Carbon Health diabetes program, a test of data

Why we need to separate burnout from moral injury in health care

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

White House drug czar issues call for 'recovery

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Apple is now the first public company to be valued at $3 trillion

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Virginia high school admissions case could be legal follow

New guidelines on severe brain injury complicate already difficult decisions

Hepatitis C has a cure — but many Americans still lack access to it

New guidelines on severe brain injury complicate already difficult decisions

Peter Hotez and the public health issue of online harassment

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Apple is now the first public company to be valued at $3 trillion

WATCH: Why do fingernails fall off when they're damaged?

knowledge

#NeedHerScience: shining a light on gender disparities in medicine

A letter from the executive editor: STAT UnitedHealth investigation

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

NIH chief: government has fallen behind pharma on clinical trials

Study suggests Covid rebound is far more common with Paxlovid than without

hotspot

hotspot

hotspot

knowledge